For instance, Liu et al. proposed that TRAF6 might be considered as a potential target for the treatment of Multiple myeloma (MM) as the receptor activator of nuclear factor-kappaB/receptor activator of nuclear factor-kappa B ligand/tumor necrosis factor receptor-associated factor (RANK/RANKL-TRAF6) signal pathway mediated osteolytic bone lesions [22]. This evidence concerns the gene TRAF6 and Miyoshi myopathy.